Critical Analysis: Immunocore (NASDAQ:IMCR) versus Cytokinetics (NASDAQ:CYTK)

Immunocore (NASDAQ:IMCR – Get Free Report) and Cytokinetics (NASDAQ:CYTK – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk and institutional ownership.

Insider and Institutional Ownership

84.5% of Immunocore shares are held by institutional investors. 10.1% of Immunocore shares are held by insiders. Comparatively, 2.6% of Cytokinetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for Immunocore and Cytokinetics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immunocore 2 3 6 1 2.50
Cytokinetics 1 1 19 0 2.86

Immunocore presently has a consensus target price of $52.86, indicating a potential upside of 83.02%. Cytokinetics has a consensus target price of $106.67, indicating a potential upside of 100.61%. Given Cytokinetics’ stronger consensus rating and higher possible upside, analysts clearly believe Cytokinetics is more favorable than Immunocore.

Profitability

This table compares Immunocore and Cytokinetics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Immunocore -7.48% -7.96% -2.93%
Cytokinetics -686.63% N/A -48.26%

Risk and Volatility

Immunocore has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500.

Earnings & Valuation

This table compares Immunocore and Cytokinetics”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Immunocore $400.02 million 3.72 -$35.51 million ($0.65) -44.43
Cytokinetics $88.04 million 84.13 -$784.96 million ($6.04) -8.80

Immunocore has higher revenue and earnings than Cytokinetics. Immunocore is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Summary

Immunocore beats Cytokinetics on 9 of the 15 factors compared between the two stocks.

About Immunocore

(Get Free Report)

Immunocore is a biotechnology company that develops T cell receptor (TCR)-based medicines for cancer and other diseases. Its ImmTAX platform is designed to create therapies that direct the body’s T cells toward targets inside cells, including targets that may be difficult for conventional antibody treatments to reach. The company’s marketed medicine, KIMMTRAK (tebentafusp-tebn), is a TCR-based therapy approved in the United States and other markets for certain patients with unresectable or metastatic uveal melanoma.

About Cytokinetics

(Get Free Report)

Cytokinetics is a biopharmaceutical company focused on discovering and developing medicines that target the biology of muscle function. Its research centers on therapies for conditions involving impaired cardiac muscle performance. The company’s work includes aficamten, a cardiac myosin inhibitor developed for hypertrophic cardiomyopathy, and other drug candidates designed to affect muscle contraction. Cytokinetics conducts research and clinical development through programs that may involve patients and collaborators in multiple countries.

Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.